BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Jan 16, 2006
 |  BioCentury  |  Product Development

Airing out the bone growth space

Alkermes Inc. and Eli Lilly and Co. say their latest deal, to develop an inhaled version of LLY's Forteo parathyroid hormone for osteoporosis, will do three things: level the playing field in the osteoporosis marketplace; lead to better outcomes due to improved compliance; and leverage administrative, formulation and manufacturing experience from their three ongoing deals.

Forteo's selling proposition is that it stimulates formation of bone, unlike other marketed products, which arrest bone loss. But since most osteoporosis medications are oral, selling an injectable product like Forteo is an uphill battle.

Moreover, Forteo soon is likely to be joined by another injectable bone building agent, Preos/Preotact injectable recombinant human PTH from NPS Pharmaceuticals Inc. (NPSP, Salt Lake City, Utah). Preos has a March 10 PDUFA date and also is under review in...

Read the full 672 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >